Focus Workshop Slides 2010 June
Program of EBF Workshop “Connecting Strategies on Dried Blood Spots” June 17-18, 2010
PDF renditions of the powerpoint presentations can be viewed and downloaded from this page by clicking the specific point on the program. The program itself can be viewed and downloaded by clicking here
| Day 1 – 17 JUNE 2010 | ||
| 08:30 – 08:40 | Welcome & Introduction EBF | |
| 08:40 – 09:10 | Plenary session | Philip Timmerman (J&J, EBF) |
| 09:10 – 10:50 | DBS in the non regulated environment Session | |
| K. Beaumont (Pfizer) | Who decided we should measure plasma? | |
| F. Picard (Novartis) | “An overview of the implementation of Dried Blood Spots (DBS) at Novartis: results and next step” | |
| P. Wright (Pfizer) | Dried Blood Spots for Metabolite Identification: Can we ? Should we ? | |
| C. Smith (AstraZeneca) | Metabolite profiles from Dried Biofluid Spots for Metabonomic studies using UPLC combined with oaTOF-MS | |
| panel discussion | ||
| 10:50 – 11:20 | Break | |
| 11:20 – 12:30 | Combined Poster and tutorial | |
| tutorial 1 | Sampling from small animals (moderator identified) | |
| tutorial 2 | Practical aspects of spotting on cards (moderator identified) | |
| tutorial 3 | Instrumental aspects of card punching (moderator identified) | |
| tutorial 4 | Sampling in the clinic or in phase 3 trials | |
| tutorial 5 | Logistics and regulatory aspects of shipping of cards | |
| 12:30 – 13:30 | Lunch | |
| 13:30 – 15:30 | Combined Tox/regulatory/QA Session | |
| TOX | ||
| F. McClure (GSK) | Spot the Difference – effect of TK blood sampling on Clinical Pathology parameters | |
| L. Patrone (BMS) | Direct Comparison of Dried Blood Spot (DBS) Analysis to Plasma and Whole Blood Analysis in Toxicokinetic Studies of Rats | |
| J. Burnett (Covance) | Practical Application of Dried Blood Spot Techniques in Toxicology | |
| REG/QA | ||
| M. Benton (Fulcrum Pharma) | QA perspective on Dried Blood Spot analysis | |
| panel discussion | ||
| 15:30 – 16:00 | Break | |
| 16:00 -18:00 | Bioanalytical and DBS: applications | |
| P. Abu-Rabie (GSK) | Direct quantitative bioanalysis of drugs in dried blood spot samples | |
| H. Ghobarah (AB Sciex) | High Sensitivity LC/MS/MS Quantification of Corticosteroids in Dried Blood Spots and Evaluation of Software Saturation Correction for Extending Dynamic Range | |
| M. Barfield (GSK) | The use of Dried Plasma Spots (DPS) and Dried Urine Spots (DUS) for LC/MS/MS assays | |
| A. Gajate Perez (Roche) | Can Dried Blood Spot technique be used to stabilize ester pro-drugs and glucuronide metabolites? | |
| M. Hemsley (Covance) | Quantitative Determination of a Therapeutic Peptide in Dried Blood Spots | |
| panel discussion | ||
| 18:00 – 19:00 | Complementary cocktail reception | |
| Day 2 – 18 JUNE 2010 | ||
| 08:30 – 10:00 | Clinical Session | |
| A. Van Peer (J&J) | Blood and plasma: a magic twin in pharmacokinetics ? | |
| HC Pandya (Univ. of Leicester) | PK studies in Infants and Children: are dried blood spots the answer ? | |
| L. Stolk (Univ. Maastricht) | Dried blood spot methods in therapeutic drug monitoring: methods, assays and pitfalls | |
| T. de Boer (Xendo) | Extensive utilisation of Dried Blood Spot sampling in early clinical development studies: pharmacokinetics, pharmacogenomics and safety assessments | |
| panel discussion | ||
| 10:00 – 10:30 | Break | |
| 10:30 – 11:30 | Bioanalytical and DBS: tools | |
| B. Ooms (Spark Holland) | on-line DBS-SPE-MS/MS – feasibility of a concept for rapid DBS analysis without punching | |
| G. Harland (Waters) | The Use of an Integrated Micro Fluidic LC/MS/MS Device for DBS Assays an Approach to Increased Sensitivity | |
| J. Dinan (BSD Robotics) | BSD robotics: bringing the DBS advantage into the Laboratory | |
| 11:30 – 12:30 | Lunch | |
| 12:30 – 13:30 | breakouts/discipline | |
| in preparation of panel discussion | DBS and discovery/non regulated environment | |
| 2 moderators | DBS and toxicology | |
| DBS in the clinic | ||
| Bioanalytical challenges for DBS | ||
| 13:30 – 14:30 | Breakout FB – Panel Discussion and conclusion | |
| 5 min comments/feedback from each break out | ||
| final panel discussion | ||
| conclusion of the meeting | ||
| 14:30 | adjourn | |
